» Articles » PMID: 9746763

Induction of Endothelial PAS Domain Protein-1 by Hypoxia: Characterization and Comparison with Hypoxia-inducible Factor-1alpha

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1998 Sep 25
PMID 9746763
Citations 176
Authors
Affiliations
Soon will be listed here.
Abstract

Hypoxia results in adaptive changes in the transcription of a range of genes including erythropoietin. An important mediator is hypoxia-inducible factor-1 (HIF-1), a DNA binding complex shown to contain at least two basic helix-loop-helix PAS-domain (bHLH-PAS) proteins, HIF-1alpha and aryl hydrocarbon nuclear receptor translocator (ARNT). In response to hypoxia, HIF-1alpha is activated and accumulates rapidly in the cell. Endothelial PAS domain protein 1 (EPAS-1) is a recently identified bHLH-PAS protein with 48% identity to HIF-1alpha, raising the question of its role in responses to hypoxia. We developed specific antibodies and studied expression and regulation of EPAS-1 mRNA and protein across a range of human cell lines. EPAS-1 was widely expressed, and strongly induced by hypoxia at the level of protein but not mRNA. Comparison of the effect of a range of activating and inhibitory stimuli showed striking similarities in the EPAS-1 and HIF-1alpha responses. Although major differences were observed in the abundance of EPAS-1 and HIF-1alpha in different cell types, differences in the inducible response were subtle with EPAS-1 protein being slightly more evident in normoxic and mildly hypoxic cells. Functional studies in a mutant cell line (Ka13) expressing neither HIF-1alpha nor EPAS-1 confirmed that both proteins interact with hypoxically responsive targets, but suggest target specificity with greater EPAS-1 transactivation (relative to HIF-1alpha transactivation) of the VEGF promoter than the LDH-A promoter.

Citing Articles

Hypoxia and the endometrium: An indispensable role for HIF-1α as therapeutic strategies.

Dai W, Guo R, Na X, Jiang S, Liang J, Guo C Redox Biol. 2024; 73:103205.

PMID: 38815332 PMC: 11167393. DOI: 10.1016/j.redox.2024.103205.


The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia.

Lawson H, Holt-Martyn J, Dembitz V, Kabayama Y, Wang L, Bellani A Nat Cancer. 2024; 5(6):916-937.

PMID: 38637657 PMC: 11208159. DOI: 10.1038/s43018-024-00761-w.


UBE3B promotes breast cancer progression by antagonizing HIF-2α degradation.

Wang Y, Liu X, Wang M, Wang Y, Wang S, Jin L Oncogene. 2023; 42(46):3394-3406.

PMID: 37783786 DOI: 10.1038/s41388-023-02842-z.


The SUMOylation and ubiquitination crosstalk in cancer.

Li K, Xia Y, He J, Wang J, Li J, Ye M J Cancer Res Clin Oncol. 2023; 149(17):16123-16146.

PMID: 37640846 DOI: 10.1007/s00432-023-05310-z.


HIF-1α promotes astrocytic production of macrophage migration inhibitory factor following spinal cord injury.

Hao H, Hou Y, Li A, Niu L, Li S, He B CNS Neurosci Ther. 2023; 29(12):3802-3814.

PMID: 37334735 PMC: 10651974. DOI: 10.1111/cns.14300.